Core Viewpoint - Gilead Sciences has agreed to acquire the remaining shares of Arcellx, valuing the deal at $7.8 billion, leading to a significant increase in Arcellx's share price towards a new record [1] Company Summary - Gilead Sciences is expanding its portfolio by purchasing the remaining equity of Arcellx, a biotechnology company, indicating a strategic move to enhance its market position [1] - Arcellx's shares experienced a notable surge in early trading, reflecting positive investor sentiment following the acquisition announcement [1]

Core Viewpoint - uniQure N.V. is set to report its fourth quarter and full year 2025 financial results on March 2, 2026, highlighting its ongoing commitment to advancing gene therapies for severe medical conditions [1]. Group 1: Financial Reporting - The financial results will be announced before market open on March 2, 2026, followed by a conference call at 8:00 a.m. ET [1]. - The event will be accessible via webcast on uniQure's website, with a replay available for 90 days post-event [2]. Group 2: Company Overview - uniQure is recognized for its pioneering work in gene therapy, particularly for hemophilia B, marking a significant milestone in genomic medicine [3]. - The company is advancing a pipeline of proprietary gene therapies targeting conditions such as Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease, among others [3].

its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC o ...

Core Insights - Gilead Sciences has agreed to acquire the remaining stake in development partner Arcellx, valuing the biotechnology company at approximately $7.8 billion upon closing [1] Company Summary - The acquisition signifies Gilead Sciences' commitment to expanding its portfolio in the biotechnology sector [1] - Arcellx is positioned to enhance Gilead's capabilities in developing innovative therapies [1]

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.By [Callum Keown]ShareResize---ReprintsIn this ...

Core Viewpoint - GeneDx Holdings Corp. reported its financial results for the fourth quarter and full year of 2025, indicating significant developments in its performance and strategic direction [1]. Financial Performance - The company disclosed its financial results for Q4 and the entire year of 2025, highlighting key metrics that reflect its operational efficiency and market position [1].

Core Viewpoint - Gilead Sciences, Inc. has announced a definitive agreement to acquire Arcellx for an implied equity value of $7.8 billion, which includes $115 per share in cash and a contingent value right of $5 per share [1] Company Overview - Gilead Sciences is a biopharmaceutical company focused on innovative medicines for life-threatening diseases, including cancer, with a commitment to advancing public health [12] - Arcellx is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other incurable diseases [11] Transaction Details - The acquisition is expected to close in the second quarter of 2026, pending customary closing conditions and regulatory approvals [7] - Gilead currently owns approximately 11.5% of Arcellx's outstanding common stock [7] - The offer price represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of February 20, 2026 [8] Product Pipeline - Gilead and Arcellx are collaborating on anitocabtagene autoleucel (anito-cel), a CAR T-cell therapy for multiple myeloma, which has shown deep and durable responses in clinical studies [2][3] - The Biologics License Application (BLA) for anito-cel has been accepted by the FDA, with a Prescription Drug User Fee Act (PDUFA) action date set for December 23, 2026 [4] Strategic Importance - Gilead's CEO emphasized the potential of anito-cel to become a foundational treatment for multiple myeloma and its importance in the company's oncology and inflammation efforts [5] - Arcellx's D-Domain CAR technology platform offers proprietary target-binding domains that could enhance future CAR T-cell and bispecific therapies [5] Financial Implications - The transaction is expected to be accretive to Gilead's earnings per share in 2028 and beyond, contingent upon FDA approval of anito-cel [9]

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer [Accessibility Statement] Skip NavigationSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo) Ross into the newly created role of Chief Development Officer. In this role, Dr. Ross will be responsible for leading early clinical development for IDEAYA's ...

Core Viewpoint - The weight loss drug market is projected to reach nearly $100 billion by the end of the decade, presenting significant opportunities for companies like Viking Therapeutics, which is advancing its obesity treatment candidate VK2735 through clinical trials [4][2]. Group 1: Market Potential - The weight loss drug market is expected to grow substantially, with analysts predicting it will approach $100 billion by the end of the decade, indicating high demand and room for multiple companies to succeed [4]. - Demand for weight loss drugs has previously outstripped supply from major players like Eli Lilly and Novo Nordisk, suggesting that new entrants like Viking could capture market share as they deliver promising clinical results [5]. Group 2: Company Growth Potential - Viking Therapeutics has a current market value of approximately $3.5 billion, which allows for significant growth potential if it secures product approvals and generates revenue [8]. - A tenfold increase in market value could elevate Viking's market cap to $35 billion, contingent on the success of its product pipeline [8]. Group 3: Stock Performance and Investor Sentiment - Viking's stock experienced a notable surge of 121% following positive phase 2 trial data for VK2735, indicating strong investor interest and potential for future gains [10]. - Although the stock has since retraced some of its gains, the initial spike demonstrates that investors are closely monitoring Viking for any positive developments, which could lead to further stock appreciation [10][11].

Core Viewpoint - Iovance Biotherapeutics is positioned for significant growth due to its recent product approval and ongoing studies across multiple cancer indications, making it an attractive investment opportunity in the biotech sector [4][10]. Company Overview - Iovance Biotherapeutics has achieved approval for its first product, lifileucel, commercialized as Amtagvi, which targets melanoma that cannot be completely removed by surgery or has metastasized [4]. - The company has a market capitalization of $1.1 billion, with current stock trading at $2.87 [5][6]. Financial Performance - Iovance is not yet profitable, which is typical for biotech firms at this stage, but it reported a 13% increase in revenue to $68 million in the latest quarter [7]. - The stock has shown a price range of $1.64 to $5.88 over the past 52 weeks, indicating volatility and potential for growth [6]. Product and Treatment Efficacy - Amtagvi is a tumor-infiltrating lymphocyte (TIL) treatment that reinvigorates a patient's own TIL to combat cancer cells [6]. - A recent study indicated a 52% objective response rate for Amtagvi in real-world conditions, surpassing the 31% response rate from the clinical trial that led to its accelerated approval [8]. Pipeline and Future Prospects - Iovance is exploring lifileucel for various cancer types and in combination with other treatments, with many trials currently in phase 2, suggesting potential for additional indications soon [9]. - The stock is accessible for investors at under $3, with the potential for significant appreciation if the pipeline proves successful [10].